Monte Rosa Therapeutics, Inc. (GLUE)

Market Cap	313.12M
Revenue (ttm)	177.99M
Net Income (ttm)	24.17M
Shares Out	61.76M
EPS (ttm)	0.29
PE Ratio	16.72
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,493
Open	4.88
Previous Close	4.92
Day's Range	4.78 - 5.11
52-Week Range	3.50 - 12.40
Beta	1.42
Analysts	Buy
Price Target	13.50 (+166.27%)
Earnings Date	Aug 7, 2025

About GLUE

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 24, 2021
• Employees: 134
• Stock Exchange: NASDAQ
• Ticker Symbol: GLUE
• Website: https://www.monterosatx.com

Analyst Summary

According to 2 analysts, the average rating for GLUE stock is "Buy." The 12-month stock price target is $13.5, which is an increase of 166.27% from the latest price.

Price Target

$13.5

(166.27% upside)

Analyst Consensus: Buy